The U.S. Food and Drug Administration has approved the Nucleus® Hybrid™ L24 Cochlear Implant System (also referred to as “Hybrid L24”) to be marketed. This is a cochlear implant system used to treat certain hearing losses caused by a defective inner ear function. The Hybrid L24 is designed to allow patients to hear in two ways: electrically (similar to approved cochlear implants) for severe to profound hearing loss at mid and high frequencies, and acoustically (similar to hearing aids) for normal to moderate hearing loss at low frequencies. For more information, please see http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm392836.htm
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
